Results 201 to 210 of about 143,709 (342)

CD20+ B Cell Depletion Alters T Cell Homing [PDF]

, 2014
Yolanda S. Kap, Nikki van Driel, Jon D. Laman, Paul P. Tak, Bert A. ‘t Hart   +4 more
openalex   +1 more source

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Alimentary Pharmacology &Therapeutics, EarlyView.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann   +4 more
wiley   +1 more source

Characterization of immune cells in periodontitis using a new histological immunologic gingival (IG) score. [PDF]

Sci Rep
Hascoët E, Blanchard F, Boutet MA, Dutilleul M, Guicheux J, Lesclous P, Cloitre A.   +6 more
europepmc   +1 more source

Canine CD20 gene

Canine CD20 gene
The human CD20 antigen, a 35 kDa cell surface nonglycosylated hydrophobic phoshpoprotein is expressed consistently on almost all human B-cells, and its monoclonal antibody is used for the therapy on human B-cell lymphoma. In the present study, canine CD20 gene was cloned and sequenced, and the expression of CD20 mRNA was investigated in canine ...
openaire  

Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review [PDF]

, 2018
Alexandros Makis, Zoi Kanta, Dimitrios Kalogeropoulos, Nikoloaos Chaliasos   +3 more
openalex   +1 more source

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL‐321

British Journal of Haematology, EarlyView.
Summary BRUIN CLL‐321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression‐free survival (PFS) compared to investigator's choice (IC) of ...
Shuhua Yi, Jiang Cao, Ru Feng, Keshu Zhou, Lihua Qiu, Fei Li, Hai Yan Yang, Hui Zhou, Wuhan Hui, Jie Cui, He Huang, Jiankun Zhu, Xiuhui Ye, Jeff Sharman, Lugui Qiu   +14 more
wiley   +1 more source

A rare case of IgG4-related disease causing inflammatory breast mass successfully treated with anti-CD20 biological therapy: a discussion of clinical case with literature review

Sufian Rifaei, Shahd Etoom, Mahmoud Al-Balas   +2 more
openalex   +2 more sources

Evaluation of CD3 and CD20 Lymphocytes and Mast Cells in the Microenvironment of Central Giant Cell Granuloma, Peripheral Giant Cell Granuloma, and Giant Cell Tumor of Bone. [PDF]

Diagnostics (Basel)
Fayaq KA, Gharib BT.
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome: an extended follow-up. [PDF]

Front Immunol
Colucci M, Riganati M, Zotta F, Gargiulo A, Massella L, Ruggiero B, Cotugno N, Ricci G, Palma P, Emma F, Vivarelli M.   +10 more
europepmc   +1 more source